Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671226 | 1.00 | MGAM (0.42) | MGAMGAASIMGAM2GPR183 | |
| SCHEMBL3677215 | 0.91 | NFE2L2 (0.43) | NFE2L2IDO1 | |
| SCHEMBL3677218 | 0.91 | NFE2L2 (0.43) | NFE2L2IDO1 | |
| SCHEMBL6548881 | 0.83 | APP (0.41) | NFE2L2IDO1MEN1KMT2A | |
| SCHEMBL827520 | 0.83 | GPR183 (0.43) | MGAMGAASIMGAM2GPR183 | |
| SCHEMBL826614 | 0.83 | MAPT (0.42) | NFE2L2MAPTL3MBTL1IDO1NPC1 | |
| SCHEMBL827519 | 0.83 | GPR183 (0.43) | MGAMGAASIMGAM2GPR183 | |
| SCHEMBL3675629 | 0.83 | MAPT (0.42) | NFE2L2MAPTL3MBTL1IDO1NPC1 | |
| SCHEMBL3677329 | 0.83 | MAPT (0.42) | NFE2L2MAPTL3MBTL1IDO1NPC1 | |
| SCHEMBL3675632 | 0.83 | MAPT (0.42) | NFE2L2MAPTL3MBTL1IDO1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1223923-A4 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | COSENZA STEPHEN C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| EP-1180024-B1 | Z-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | COSENZA STEPHEN C (US) | 2003-08-07 | — | — | US | disclosed |
| US-6576675-B1 | Such as 4-fluorostyryl-4-iodobenzylsulfone; targeting receptor tyrosine kinases | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-06-10 | — | — | US | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414034-B1 | ANTICANCER AGENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-07-02 | — | — | US | disclosed |
| EP-1180024-A4 | Z-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1180024-A1 | Z-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| US-6201154-B1 | Z-styryl sulfone anticancer agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION | 2001-03-13 | — | — | US | disclosed |
| WO-2000057872-A1 | Z-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TOP1, TOP2A, PCNA | MGAM 3031/4885GAA 1602/4885SI 317/4885 |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | CCNE1, CCNE2, TOP2B | MGAM 3028/4885GAA 1789/4885SI 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.